Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 19, 2025

Project Blackhawk: Transportable GMP Plasmid Facility with POD® Cleanrooms

Author(s)G-CON

In this video, discover how G-CON partnered with NIIMBL on Project Blackhawk, transforming a 50-year-old warehouse into a GMP-like plasmid production facility using prefabricated POD® Cleanrooms. This innovative POD®-based approach integrated all utility systems, allowed renovation and construction to happen in parallel, and drastically accelerated the project timeline. The result: a demonstration of how GMP-capable facilities can be mobile, rapidly deployable, and adaptable even in minimal infrastructure environments. The project was supported with funding from the National Institute of Standards and Technology in the Department of Commerce under 70NANB21H085.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.